Garetosmab
Sources
registry, as of 2026-09-01Stale
https://clinicaltrials.gov/study/NCT06299098
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 1005. Conditions Obesity. This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the
ClinicalTrials.gov NCT06299098 protocol and results modules
registry, as of 2025-09-17Stale
https://clinicaltrials.gov/study/NCT06970405
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women. Overall status WITHDRAWN. Phases PHASE1. Lead sponsor Regeneron Pharmaceuticals. Enrollment 0. Conditions Obesity. This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other res
ClinicalTrials.gov NCT06970405 protocol and results modules
publication, as of 2023-10-23Stale
https://pubmed.ncbi.nlm.nih.gov/37770652/
flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; n = 43). The primary end points were s
PMID 37770652